{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-040784","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2026-06-04T20:11:31+00:00","discovered_at":"2026-06-04T20:13:04.257242+00:00","generated_at":"2026-06-04T20:43:17.880909+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Globus Medical shareholders approve 1M share increase to equity plan, re-elect directors","bullets":["Stockholders approved amendment to 2021 Equity Incentive Plan, increasing authorized shares by 1,000,000 to 12,000,000.","Keith Pfeil and Robert A. Douglas re-elected as Class II directors with substantial majority support.","Deloitte & Touche LLP ratified as independent auditor for fiscal year ending December 31, 2026.","Non-binding advisory vote on 2025 executive compensation passed with 316M for vs. 5.2M against.","No other matters were submitted to stockholders at the June 3, 2026 Annual Meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-040784","json":"https://secwatch.observer/filing/0001628280-26-040784.json","markdown":"https://secwatch.observer/filing/0001628280-26-040784.md","text":"https://secwatch.observer/filing/0001628280-26-040784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/0001628280-26-040784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/gmed-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:43:17.880909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57adc7602b6f2ff8131be4f73dfdceae2907dc84","claim":"GLOBUS MEDICAL INC shareholders approved Approval of 2021 Equity Incentive Plan Amendment.","evidence_excerpt":"The Company’s stockholders approved the 2021 Equity Incentive Plan Amendment.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/0001628280-26-040784-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"808ccd924734e902ce5874ee4bb6bcb8a055449b","claim":"GLOBUS MEDICAL INC shareholders approved Approval, on a non-binding, advisory basis, of the 2025 compensation of the Company’s named executive officers.","evidence_excerpt":"The Company’s stockholders approved, on a non-binding, advisory basis the 2025 compensation of the Company’s named executive officers, as described in the Proxy Statement.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/0001628280-26-040784-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"a0d8aa709d4cc5fd5f2d6edb116c83e7bf926bd4","claim":"GLOBUS MEDICAL INC shareholders approved Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders.","evidence_excerpt":"Each of the director nominees listed below were elected by the Company’s stockholders at the Annual Meeting to serve a three-year term on the Board.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/0001628280-26-040784-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"f1c879cba5f1be761dc6905fa103c98bdc820726","claim":"GLOBUS MEDICAL INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-12-31 meeting.","evidence_excerpt":"The Company’s stockholders approved the ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026040784/0001628280-26-040784-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-12-31"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}